Unsurprisingly, the FDA's approval rate for new drugs is down. Here's the interesting quote from the story:
"There have been no systematic changes in how we are approaching the approval standards for new applications," FDA spokesman Christopher Kelly said in an e-mail. "Whether the current public debate and criticism of FDA on drug safety has played any role in our actions is very hard to quantify."

It's easy to hide behind the "hard to quantify" line, but it seems impossible to believe the scrutiny hasn't had an impact.